|Bid||0.2334 x 1000|
|Ask||0.2300 x 1000|
|Day's range||0.2019 - 0.2389|
|52-week range||0.2000 - 3.3200|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.00|
Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.
Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Clovis Oncology ( NASDAQ:CLVS ) Third Quarter 2022 Results Key Financial Results Revenue: US$30.7m (down 19% from 3Q...